D
Duquesne Family Office LLC
+ Con en carteraPURR
+8.54%
Rentabilidad a 3 meses
$9.070
-0.676 (-7.45%)Al cierre
Loading chart…
- Máximo
- 9.730
- Apertura
- 9.610
- Precio medio ponderado por volumen
- 9.26
- Volumen
- 11.77M
- Capitalización
- —
- Mínimo
- 8.980
- Importe
- 108.98M
- EV/EBITDA, TTM
- 0.37
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action.
Análisis de IA of Hyperliquid Strategies Inc (PURR)
ComprarHyperliquid Strategies Inc (PURR) is a good buy right now due to its significant growth potential and strong market position. The current price is $11.11, and analysts have set a price target of $18, which represents a potential upside of 63%. Additionally, the company has shown impressive revenue growth, with Q4 2026 revenue reaching $6.33 million, and a gross margin of 100% in the last three quarters, indicating strong profitability. However, the main risk is the ongoing investigation into insider trading, which could impact market sentiment and investor confidence.
Métricas de valoración
El PER previsto actual de Hyperliquid Strategies Inc (PURR) es 14.20, frente a su media de 5 años de 14.20.
Ballenas con PURR en cartera
Cronología de eventos
Noticias
8.510-16CNBCValuation Gap Widens Between AI Leaders OpenAI and Anthropic
7.009-29CNBCHouse Expands Investigation into Insider Trading in Prediction Markets
6.009-15CNBCLatest Rating Updates from Wall Street
8.509-15stocktwitsCompass Point Initiates Coverage on Hyperliquid Strategies with Buy Rating
2.009-07NASDAQ.COMHyperliquid Strategies Surges 94% in August 2026
Preguntas frecuentes sobre PURR, respondidas por Alphio AI
Hyperliquid Strategies Inc is a digital asset treasury company. The Company is focused on accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. The Company’s subsidiary is Sonnet BioTherapeutics Holdings, Inc., which is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bifunctional action. It operates in the Technology sector.
Hyperliquid Strategies Inc (PURR) is a good buy right now due to its significant growth potential and strong market position. The current price is $11.11, and analysts have set a price target of $18, which represents a potential upside of 63%. Additionally, the company has shown impressive revenue growth, with Q4 2026 revenue reaching $6.33 million, and a gross margin of 100% in the last three quarters, indicating strong profitability. However, the main risk is the ongoing investigation into insider trading, which could impact market sentiment and investor confidence.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.